Huntington Potter, PhD - Publications

Affiliations: 
Neurology and Linda Crnic Institute for Down Syndrome  University of Colorado, Boulder, Boulder, CO, United States 
Area:
Alzheimer's Disease, Down Syndrome

134 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 James E, Vielle A, Cusato K, Li H, Lee B, Parween S, Howell A, Johnson NR, Chial HJ, Potter H, Vergara MN. Human iPSC-derived retinal organoids develop robust Alzheimer's disease neuropathology. Frontiers in Cellular Neuroscience. 18: 1340448. PMID 38323188 DOI: 10.3389/fncel.2024.1340448  0.361
2023 Thaker AA, McConnell BV, Rogers DM, Carlson NE, Coughlan C, Jensen AM, Lopez-Paniagua D, Holden SK, Pressman PS, Pelak VS, Filley CM, Potter H, Adriana Solano D, Heffernan KS, Bettcher BM. Astrogliosis, neuritic microstructure, and sex effects: GFAP is an indicator of neuritic orientation in women. Brain, Behavior, and Immunity. PMID 37394144 DOI: 10.1016/j.bbi.2023.06.026  0.342
2023 Stonedahl S, Leser JS, Clarke P, Potter H, Boyd TD, Tyler KL. Treatment with Granulocyte-Macrophage Colony-Stimulating Factor Reduces Viral Titers in the Brains of West Nile Virus-Infected Mice and Improves Survival. Journal of Virology. e0180522. PMID 36802227 DOI: 10.1128/jvi.01805-22  0.719
2022 Lucero EM, Freund RK, Smith A, Johnson NR, Dooling B, Sullivan E, Prikhodko O, Ahmed MM, Bennett DA, Hohman TJ, Dell'Acqua ML, Chial HJ, Potter H. Increased / expression offsets Alzheimer Aβ-mediated toxicity and cognitive dysfunction. Iscience. 25: 105288. PMID 36304124 DOI: 10.1016/j.isci.2022.105288  0.344
2022 Johnson NR, Wang AC, Coughlan C, Sillau S, Lucero E, Viltz L, Markham N, Allen C, Dhanasekaran AR, Chial HJ, Potter H. Imipramine and olanzapine block apoE4-catalyzed polymerization of Aβ and show evidence of improving Alzheimer's disease cognition. Alzheimer's Research & Therapy. 14: 88. PMID 35768831 DOI: 10.1186/s13195-022-01020-9  0.363
2022 Ahmed MM, Wang AC, Elos M, Chial HJ, Sillau S, Solano DA, Coughlan C, Aghili L, Anton P, Markham N, Adame V, Gardiner KJ, Boyd TD, Potter H. The innate immune system stimulating cytokine GM-CSF improves learning/memory and interneuron and astrocyte brain pathology in Dp16 down syndrome mice and improves learning/memory in wild-type mice. Neurobiology of Disease. 105694. PMID 35307513 DOI: 10.1016/j.nbd.2022.105694  0.763
2022 Galvin J, Curran E, Arteaga F, Goossens A, Aubuchon-Endsley N, McMurray MA, Moore J, Hansen KC, Chial HJ, Potter H, Brodsky JL, Coughlan CM. Proteasome activity modulates amyloid toxicity. Fems Yeast Research. PMID 35150241 DOI: 10.1093/femsyr/foac004  0.32
2022 Potter H, Kendall L, Boyd T, Sillau S, Bosco-Lauth A, Markham N, Fong D, Clarke P, Tyler K. GM-CSF Promotes Immune Response and Survival in a Mouse Model of COVID-19. Research Square. PMID 35118463 DOI: 10.21203/rs.3.rs-1213395/v1  0.723
2021 Ahmed MM, Johnson NR, Boyd TD, Coughlan C, Chial HJ, Potter H. Innate Immune System Activation and Neuroinflammation in Down Syndrome and Neurodegeneration: Therapeutic Targets or Partners? Frontiers in Aging Neuroscience. 13: 718426. PMID 34603007 DOI: 10.3389/fnagi.2021.718426  0.734
2021 Potter H, Woodcock JH, Boyd TD, Coughlan CM, O'Shaughnessy JR, Borges MT, Thaker AA, Raj BA, Adamszuk K, Scott D, Adame V, Anton P, Chial HJ, Gray H, Daniels J, et al. Safety and efficacy of sargramostim (GM-CSF) in the treatment of Alzheimer's disease. Alzheimer's & Dementia (New York, N. Y.). 7: e12158. PMID 33778150 DOI: 10.1002/trc2.12158  0.772
2020 Bubak AN, Beseler C, Como CN, Coughlan CM, Johnson NR, Hassell JE, Burnet AM, Mescher T, Schmid DS, Coleman C, Mahalingam R, Cohrs RJ, Boyd TD, Potter H, Shilleh AH, et al. Amylin, Aβ42, and Amyloid in VZV Vasculopathy Cerebrospinal Fluid and Infected Vascular Cells. The Journal of Infectious Diseases. PMID 32809013 DOI: 10.1093/Infdis/Jiaa513  0.743
2020 Potter H, Boyd TD, Clarke P, Pelak VS, Tyler KL. Recruiting the innate immune system with GM-CSF to fight viral diseases, including West Nile Virus encephalitis and COVID-19. F1000research. 9: 345. PMID 32704352 DOI: 10.12688/F1000Research.23729.1  0.747
2020 Coughlan C, Bruce KD, Burgy O, Boyd TD, Michel CR, Garcia-Perez JE, Adame V, Anton P, Bettcher BM, Chial HJ, Koenigshoff M, Hsieh EWY, Graner M, Potter H. Exosome Isolation by Ultracentrifugation and Precipitation and Techniques for Downstream Analyses. Current Protocols in Cell Biology. 88: e110. PMID 32633898 DOI: 10.1002/Cpcb.110  0.693
2020 Snyder HM, Bain LJ, Brickman AM, Carrillo MC, Esbensen AJ, Espinosa JM, Fernandez F, Fortea J, Hartley SL, Head E, Hendrix J, Kishnani PS, Lai F, Lao P, Lemere C, ... ... Potter H, et al. Further understanding the connection between Alzheimer's disease and Down syndrome. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 32544310 DOI: 10.1002/Alz.12112  0.405
2020 Bubak AN, Beseler C, Como CN, Tyring SK, Haley C, Mescher T, Hassell JE, Cohrs RJ, Potter H, Nagel MA. Acute zoster plasma contains elevated amyloid, correlating with Aβ42 and amylin levels, and is amyloidogenic. Journal of Neurovirology. PMID 32385803 DOI: 10.1007/S13365-020-00830-7  0.407
2019 Potter H, Chial HJ, Caneus J, Elos M, Elder N, Borysov S, Granic A. Chromosome Instability and Mosaic Aneuploidy in Neurodegenerative and Neurodevelopmental Disorders. Frontiers in Genetics. 10: 1092. PMID 31788001 DOI: 10.3389/Fgene.2019.01092  0.328
2019 Bubak AN, Como CN, Coughlan CM, Johnson NR, Hassell JE, Mescher T, Niemeyer CS, Mahalingam R, Cohrs RJ, Boyd TD, Potter H, Russ HA, Nagel MA. Varicella Zoster Virus Infection of Primary Human Spinal Astrocytes Produces Intracellular Amylin, Amyloid-beta, and an Amyloidogenic Extracellular Environment. The Journal of Infectious Diseases. PMID 31665341 DOI: 10.1093/Infdis/Jiz560  0.747
2019 Potter H, Chial HJ. Targeting the Interaction Between Apolipoprotein E and Amyloid Precursor Protein: A Novel Alzheimer's Disease Therapy. Biological Psychiatry. 86: 169-170. PMID 31319935 DOI: 10.1016/J.Biopsych.2019.06.005  0.384
2019 Pelak VS, Tang-Wai DF, Bouwman FH, Onyike CU, Murray ME, Day GS, Migliaccio R, Olds J, Hills W, Bretsch C, Lusk J, Potter H, Boyd T, Pressman PS, Holden SK, et al. P1-311: Development Of An International Posterior Cortical Atrophy Bioregistry Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.866  0.695
2019 Ahmed MM, Jung Wang AC, Boyd T, Elos M, Chial HJ, Gardiner KJ, Potter H. P4-032: GM-CSF REVERSES MEMORY DEFICITS IN NORMAL AGED MICE AND IN THE DP(16)1YEY MOUSE MODEL OF DOWN SYNDROME Alzheimer's & Dementia. 15: P1286-P1287. DOI: 10.1016/J.Jalz.2019.06.3691  0.303
2017 Caneus J, Granic A, Rademakers R, Dickson DW, Coughlan CM, Chial HJ, Potter H. Mitotic Defects Lead to Neuronal Aneuploidy and Apoptosis in Frontotemporal Lobar Degeneration Caused by MAPT Mutations. Molecular Biology of the Cell. PMID 29282277 DOI: 10.1091/Mbc.E17-01-0031  0.318
2017 Hamlett ED, Ledreux A, Potter H, Chial HJ, Patterson D, Espinosa JM, Bettcher BM, Granholm AC. EXOSOMAL BIOMARKERS IN DOWN SYNDROME AND ALZHEIMER'S DISEASE. Free Radical Biology & Medicine. PMID 28882786 DOI: 10.1016/J.Freeradbiomed.2017.08.028  0.447
2017 Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, Kunkle BW, Boland A, Raybould R, Bis JC, Martin ER, Grenier-Boley B, Heilmann-Heimbach S, Chouraki V, Kuzma AB, ... ... Potter H, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics. PMID 28714976 DOI: 10.1038/Ng.3916  0.348
2017 Potter H, Woodcock JH, Boyd T, Sillau SH, Bettcher BM, Daniels J, Heffernan KS, Gray H. INTERIM REPORT OF A PHASE 2 PILOT SAFETY AND EFFICACY TRIAL OF GM-CSF/LEUKINE® IN MILD-TO-MODERATE ALZHEIMER'S DISEASE Alzheimer's & Dementia. 13: P1572. DOI: 10.1016/J.Jalz.2017.07.735  0.743
2017 Coughlan CM, Wang A, Viltz L, Chial HJ, Potter H. [P2-143]: SCREENING FOR INHIBITORS OF APOE4-CATALYZED Aβ OLIGOMER/FILAMENT FORMATION: A NOVEL APPROACH TO ALZHEIMER's DISEASE DRUG DISCOVERY Alzheimer's & Dementia. 13: P662-P663. DOI: 10.1016/J.Jalz.2017.06.793  0.372
2016 Potter H. New Genetic Links Between Alzheimer Disease and Immune-Mediated Diseases Revealed by Overlapping Genome-wide Association Study Hits. Jama Neurology. PMID 27088554 DOI: 10.1001/Jamaneurol.2016.0407  0.339
2016 Freund RK, Gibson ES, Potter H, Dell'Acqua ML. Inhibition of the motor protein Eg5/Kinesin-5 in amyloid beta-mediated impairment of hippocampal long-term potentiation and dendritic spine loss. Molecular Pharmacology. PMID 26957206 DOI: 10.1124/Mol.115.103085  0.335
2016 Potter H, Granic A, Caneus J. Role of Trisomy 21 Mosaicism in Sporadic and Familial Alzheimer's Disease. Current Alzheimer Research. 13: 7-17. PMID 26651340 DOI: 10.2174/156720501301151207100616  0.457
2016 Caneus J, Potter H. P2-114: Increased Genomic Instability and Correlated Apoptosis are Associated with Cognitive Impairment in Neurodegenerative Diseases Alzheimer's & Dementia. 12: P655-P656. DOI: 10.1016/J.Jalz.2016.06.1484  0.34
2015 Potter H. Kinesin light chain-1 variant E disrupts axonal transport and Aβ generation in Alzheimer's disease (comment on DOI 10.1002/bies.201400131). Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. 37: 118. PMID 25581896 DOI: 10.1002/Bies.201400206  0.33
2015 Wang LS, Naj AC, Graham RR, Crane PK, Kunkle BW, Cruchaga C, Murcia JD, Cannon-Albright L, Baldwin CT, Zetterberg H, Blennow K, Kukull WA, Faber KM, Schupf N, Norton MC, ... ... Potter H, et al. Rarity of the Alzheimer disease-protective APP A673T variant in the United States. Jama Neurology. 72: 209-16. PMID 25531812 DOI: 10.1001/Jamaneurol.2014.2157  0.436
2015 Hartley D, Blumenthal T, Carrillo M, DiPaolo G, Esralew L, Gardiner K, Granholm AC, Iqbal K, Krams M, Lemere C, Lott I, Mobley W, Ness S, Nixon R, Potter H, et al. Down syndrome and Alzheimer's disease: Common pathways, common goals. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 11: 700-9. PMID 25510383 DOI: 10.1016/J.Jalz.2014.10.007  0.432
2015 Caneus J, Potter H. P1-006: Association of aneuploidy with multiple neurodegenerative diseases and its possible involvement in the progression of cognitive decline Alzheimer's & Dementia. 11: P338-P338. DOI: 10.1016/J.Jalz.2015.06.202  0.366
2014 Naj AC, Jun G, Reitz C, Kunkle BW, Perry W, Park YS, Beecham GW, Rajbhandary RA, Hamilton-Nelson KL, Wang LS, Kauwe JS, Huentelman MJ, Myers AJ, Bird TD, Boeve BF, ... ... Potter H, et al. Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study. Jama Neurology. 71: 1394-404. PMID 25199842 DOI: 10.1001/Jamaneurol.2014.1491  0.339
2014 Ari C, Borysov SI, Wu J, Padmanabhan J, Potter H. Alzheimer amyloid beta inhibition of Eg5/kinesin 5 reduces neurotrophin and/or transmitter receptor function. Neurobiology of Aging. 35: 1839-49. PMID 24636920 DOI: 10.1016/J.Neurobiolaging.2014.02.006  0.411
2014 Wang A, Potter H, Bennett S, Caneus J, Ari C, Borysov S, Padmanabhan J, Wu J, Granic A. P2-011: Aβ INHIBITION OF KINESIN 5 DISRUPTS THE LOCALIZATION AND FUNCTION OF MEMBRANE PROTEINS: IMPLICATIONS FOR NEURONAL RESPONSES TO NEUROTROPHINS, NEUROTRANSMITTERS, GLUCOSE, AND LIPIDS IN AD Alzheimer's & Dementia. 10: P474-P474. DOI: 10.1016/J.Jalz.2014.05.684  0.326
2013 Duara R, Loewenstein DA, Shen Q, Barker W, Varon D, Greig MT, Curiel R, Agron J, Santos I, Potter H. The utility of age-specific cut-offs for visual rating of medial temporal atrophy in classifying Alzheimer's disease, MCI and cognitively normal elderly subjects. Frontiers in Aging Neuroscience. 5: 47. PMID 24065917 DOI: 10.3389/Fnagi.2013.00047  0.424
2013 Granic A, Potter H. Mitotic spindle defects and chromosome mis-segregation induced by LDL/cholesterol-implications for Niemann-Pick C1, Alzheimer's disease, and atherosclerosis. Plos One. 8: e60718. PMID 23593294 DOI: 10.1371/Journal.Pone.0060718  0.356
2012 Nilsson LN, Gografe S, Costa DA, Hughes T, Dressler D, Potter H. USE OF FUSED CIRCULATIONS TO INVESTIGATE THE ROLE OF APOLIPOPROTEIN E AS AMYLOID CATALYST AND PERIPHERAL SINK IN ALZHEIMER'S DISEASE. Technology and Innovation. 14: 199-208. PMID 23626867 DOI: 10.3727/194982412X13462021398010  0.707
2012 Shen Q, Zhao W, Loewenstein DA, Potter E, Greig MT, Raj A, Barker W, Potter H, Duara R. Comparing new templates and atlas-based segmentations in the volumetric analysis of brain magnetic resonance images for diagnosing Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 8: 399-406. PMID 22959698 DOI: 10.1016/J.Jalz.2011.07.002  0.355
2012 Jim HS, Boyd TD, Booth-Jones M, Pidala J, Potter H. Granulocyte Macrophage Colony Stimulating Factor Treatment is Associated with Improved Cognition in Cancer Patients. Brain Disorders & Therapy. 1. PMID 22905341 DOI: 10.4172/2168-975X.1000101  0.747
2012 Potter H, Wisniewski T. Apolipoprotein e: essential catalyst of the Alzheimer amyloid cascade. International Journal of Alzheimer's Disease. 2012: 489428. PMID 22844635 DOI: 10.1155/2012/489428  0.434
2012 Loewenstein DA, Greig MT, Schinka JA, Barker W, Shen Q, Potter E, Raj A, Brooks L, Varon D, Schoenberg M, Banko J, Potter H, Duara R. An investigation of PreMCI: subtypes and longitudinal outcomes. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 8: 172-9. PMID 22546351 DOI: 10.1016/J.Jalz.2011.03.002  0.313
2012 Cao C, Loewenstein DA, Lin X, Zhang C, Wang L, Duara R, Wu Y, Giannini A, Bai G, Cai J, Greig M, Schofield E, Ashok R, Small B, Potter H, et al. High Blood caffeine levels in MCI linked to lack of progression to dementia. Journal of Alzheimer's Disease : Jad. 30: 559-72. PMID 22430531 DOI: 10.3233/Jad-2012-111781  0.339
2012 Boyd TD, Potter H. THE JOURNEY OF A POTENTIAL ALZHEIMER THERAPY FROM THE LABORATORY BENCH THROUGH THE PATENT OFFICE AND INTO THE CLINIC Technology & Innovation. 14: 365-380. DOI: 10.3727/194982412X13500042169216  0.728
2012 Granic A, Norden M, Potter H. P2-085: Genomic damage induced by lipoproteins/cholesterol: Implications for Alzheimer's and cardiovascular disease Alzheimer's & Dementia. 8: P293-P293. DOI: 10.1016/J.Jalz.2012.05.789  0.34
2012 Cao C, Lin X, Wang W, Li Y, Cai J, Raj B, Potter H. P2-004: The role of CD8 T cell and its receptor change in Alzheimer's disease Alzheimer's & Dementia. 8: P265-P265. DOI: 10.1016/J.Jalz.2012.05.707  0.313
2011 Judge M, Hornbeck L, Potter H, Padmanabhan J. Mitosis-specific phosphorylation of amyloid precursor protein at threonine 668 leads to its altered processing and association with centrosomes. Molecular Neurodegeneration. 6: 80. PMID 22112898 DOI: 10.1186/1750-1326-6-80  0.423
2011 Shen Q, Loewenstein DA, Potter E, Zhao W, Appel J, Greig MT, Raj A, Acevedo A, Schofield E, Barker W, Wu Y, Potter H, Duara R. Volumetric and visual rating of magnetic resonance imaging scans in the diagnosis of amnestic mild cognitive impairment and Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 7: e101-8. PMID 21784342 DOI: 10.1016/J.Jalz.2010.07.002  0.403
2011 Borysov SI, Granic A, Padmanabhan J, Walczak CE, Potter H. Alzheimer Aβ disrupts the mitotic spindle and directly inhibits mitotic microtubule motors. Cell Cycle (Georgetown, Tex.). 10: 1397-410. PMID 21566458 DOI: 10.4161/Cc.10.9.15478  0.318
2011 Varon D, Loewenstein DA, Potter E, Greig MT, Agron J, Shen Q, Zhao W, Celeste Ramirez M, Santos I, Barker W, Potter H, Duara R. Minimal atrophy of the entorhinal cortex and hippocampus: progression of cognitive impairment. Dementia and Geriatric Cognitive Disorders. 31: 276-83. PMID 21494034 DOI: 10.1159/000324711  0.327
2011 Duara R, Loewenstein DA, Greig MT, Potter E, Barker W, Raj A, Schinka J, Borenstein A, Schoenberg M, Wu Y, Banko J, Potter H. Pre-MCI and MCI: neuropsychological, clinical, and imaging features and progression rates. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 19: 951-60. PMID 21422909 DOI: 10.1097/Jgp.0B013E3182107C69  0.333
2011 Potter H. Alzheimer's insight New Scientist. 211: 32. DOI: 10.1016/S0262-4079(11)61900-3  0.406
2011 Potter H, Jim H, Boyd T, Booth-Jones M, Pidala J. O3-07-07: Potential Alzheimer's treatments GM-CSF and G-CSF improve cognition in cancer patients Alzheimer's & Dementia. 7: S514-S514. DOI: 10.1016/J.Jalz.2011.05.1438  0.351
2010 Schinka JA, Loewenstein DA, Raj A, Schoenberg MR, Banko JL, Potter H, Duara R. Defining mild cognitive impairment: impact of varying decision criteria on neuropsychological diagnostic frequencies and correlates. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 18: 684-91. PMID 21399729 DOI: 10.1097/Jgp.0B013E3181E56D5A  0.343
2010 Boyd TD, Bennett SP, Mori T, Governatori N, Runfeldt M, Norden M, Padmanabhan J, Neame P, Wefes I, Sanchez-Ramos J, Arendash GW, Potter H. GM-CSF upregulated in rheumatoid arthritis reverses cognitive impairment and amyloidosis in Alzheimer mice. Journal of Alzheimer's Disease : Jad. 21: 507-18. PMID 20555144 DOI: 10.3233/Jad-2010-091471  0.783
2010 Duara R, Loewenstein DA, Greig M, Acevedo A, Potter E, Appel J, Raj A, Schinka J, Schofield E, Barker W, Wu Y, Potter H. Reliability and validity of an algorithm for the diagnosis of normal cognition, mild cognitive impairment, and dementia: implications for multicenter research studies. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 18: 363-70. PMID 20306566 DOI: 10.1097/Jgp.0B013E3181C534A0  0.353
2010 Abisambra JF, Fiorelli T, Padmanabhan J, Neame P, Wefes I, Potter H. LDLR expression and localization are altered in mouse and human cell culture models of Alzheimer's disease. Plos One. 5: e8556. PMID 20049331 DOI: 10.1371/Journal.Pone.0008556  0.715
2010 Granic A, Padmanabhan J, Norden M, Potter H. Alzheimer Abeta peptide induces chromosome mis-segregation and aneuploidy, including trisomy 21: requirement for tau and APP. Molecular Biology of the Cell. 21: 511-20. PMID 20032300 DOI: 10.1091/Mbc.E09-10-0850  0.446
2010 Schinka JA, Raj A, Loewenstein DA, Small BJ, Duara R, Potter H. Cross-validation of the Florida Cognitive Activities Scale (FCAS) in an Alzheimer's disease research center sample. Journal of Geriatric Psychiatry and Neurology. 23: 9-14. PMID 19703991 DOI: 10.1177/0891988709342724  0.367
2010 Schinka JA, Raj A, Loewenstein DA, Small BJ, Duara R, Potter H. The cognitive change checklist (3CL): cross-validation of a measure of change in everyday cognition. International Journal of Geriatric Psychiatry. 25: 266-74. PMID 19575419 DOI: 10.1002/Gps.2332  0.341
2010 Duara R, Loewenstein DA, Greig-Custo MT, Raj A, Barker W, Potter E, Schofield E, Small B, Schinka J, Wu Y, Potter H. Diagnosis and staging of mild cognitive impairment, using a modification of the clinical dementia rating scale: the mCDR. International Journal of Geriatric Psychiatry. 25: 282-9. PMID 19565573 DOI: 10.1002/Gps.2334  0.338
2010 Potter H, Granic A, Borysov S, Abisambra JF, Padmanabhan J, Wefes I, Goodwin B, Neame P, Fiorelli T, Norden M. P4-005: Alzheimer Aβ Induces Chromosome Mis-segregation, Microtubule Defects, Receptor Mis-localization, and Inhibition of Mitotic/Neuronal Kinesins: Implications for Neurogenesis and Plasticity in Neurodegenrative Diseases Alzheimer's & Dementia. 6: e22-e22. DOI: 10.1016/J.Jalz.2010.08.066  0.671
2010 Varon D, Potter E, Rodriguez M, Barker W, Raj BA, Loewenstein D, Potter H, Duara R. Correlating minimal atrophy of hippocampus (HPC) and entorhinal cortex (ERC) with memory and functional ability among elderly subjects Alzheimers & Dementia. 6. DOI: 10.1016/J.Jalz.2010.05.023  0.362
2009 Bennett SP, Boyd TD, Norden M, Padmanabhan J, Neame P, Wefes I, Potter H. A novel technique for simultaneous bilateral brain infusions in a mouse model of neurodegenerative disease. Journal of Neuroscience Methods. 184: 320-6. PMID 19732796 DOI: 10.1016/J.Jneumeth.2009.08.021  0.781
2009 Appel J, Potter E, Bhatia N, Shen Q, Zhao W, Greig MT, Raj A, Barker WW, Potter H, Schofield E, Wu Y, Loewenstein DA, Duara R. Association of white matter hyperintensity measurements on brain MR imaging with cognitive status, medial temporal atrophy, and cardiovascular risk factors. Ajnr. American Journal of Neuroradiology. 30: 1870-6. PMID 19643919 DOI: 10.3174/Ajnr.A1693  0.39
2009 Cao C, Cirrito JR, Lin X, Wang L, Wang L, Verges DK, Dickson A, Mamcarz M, Zhang C, Mori T, Arendash GW, Holtzman DM, Potter H. Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer's disease transgenic mice. Journal of Alzheimer's Disease : Jad. 17: 681-97. PMID 19581723 DOI: 10.3233/Jad-2009-1071  0.459
2009 Arendash GW, Mori T, Cao C, Mamcarz M, Runfeldt M, Dickson A, Rezai-Zadeh K, Tane J, Citron BA, Lin X, Echeverria V, Potter H. Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice. Journal of Alzheimer's Disease : Jad. 17: 661-80. PMID 19581722 DOI: 10.3233/Jad-2009-1087  0.746
2008 Duara R, Loewenstein DA, Potter E, Appel J, Greig MT, Urs R, Shen Q, Raj A, Small B, Barker W, Schofield E, Wu Y, Potter H. Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer disease. Neurology. 71: 1986-92. PMID 19064880 DOI: 10.1212/01.Wnl.0000336925.79704.9F  0.404
2008 Cao C, Lin X, Zhang C, Wahi MM, Wefes I, Arendash G, Potter H. Mutant amyloid-beta-sensitized dendritic cells as Alzheimer's disease vaccine. Journal of Neuroimmunology. 200: 1-10. PMID 18649951 DOI: 10.1016/J.Jneuroim.2008.05.017  0.306
2008 Cao C, Lin X, Wahi MM, Jackson EA, Potter H. Successful adjuvant-free vaccination of BALB/c mice with mutated amyloid beta peptides. Bmc Neuroscience. 9: 25. PMID 18282292 DOI: 10.1186/1471-2202-9-25  0.319
2008 Leighty RE, Runfeldt MJ, Berndt DJ, Schleif WS, Cracchiolo JR, Potter H, Arendash GW. Use of artificial neural networks to determine cognitive impairment and therapeutic effectiveness in Alzheimer's transgenic mice. Journal of Neuroscience Methods. 167: 358-66. PMID 17904642 DOI: 10.1016/J.Jneumeth.2007.08.008  0.804
2008 Boeras DI, Granic A, Padmanabhan J, Crespo NC, Rojiani AM, Potter H. Alzheimer's presenilin 1 causes chromosome missegregation and aneuploidy. Neurobiology of Aging. 29: 319-28. PMID 17169464 DOI: 10.1016/J.Neurobiolaging.2006.10.027  0.735
2008 Arendash GW, Mamcarz M, Dickson A, Wang L, Xiaoyang L, Cao C, Potter H. P1-068: Environmental enrichment “sessions” are sufficient to provide cognitive benefit to impaired Alzheimer's transgenic mice without affecting brain or plasma Aβ levels Alzheimer's & Dementia. 4: T226-T226. DOI: 10.1016/J.Jalz.2008.05.654  0.446
2008 Cao C, Lin X, Zhang C, Breitenkamp K, Wang L, Dillingham C, Potter H. O3-05-06: Nanoparticle Alzheimer's disease vaccine targeting oligomeric Abeta Alzheimer's & Dementia. 4: T169-T169. DOI: 10.1016/J.Jalz.2008.05.446  0.334
2008 Arendash GW, Cao C, Mori T, Mamcartz M, Dickson A, Wang L, Runfelt M, Rezai-zadeh K, Tan J, Xiaoyang L, Potter H. O1-04-04: Caffeine reverses cognitive impairment, decreases β-amyloid levels, and reduces inflammation in aged Alzheimer's mice: Implications for Alzheimer's treatment Alzheimer's & Dementia. 4: T115-T115. DOI: 10.1016/J.Jalz.2008.05.241  0.73
2008 Granic A, Potter H. P4-302: Lipoprotein-induced chromosome missegregation in vitro and in vivo: Implications for cardiovascular and Alzheimer's disease Alzheimer's & Dementia. 4: T760-T760. DOI: 10.1016/J.Jalz.2008.05.2372  0.358
2008 Cao C, Lin X, Zhang C, Dickson A, Mamcarz M, Wang L, Arendash G, Potter H. IC-P3-174: Plasma Aβ level can be used as marker for AD treatment in PS1/APP Alzheimer's mouse model Alzheimer's & Dementia. 4: T77-T77. DOI: 10.1016/J.Jalz.2008.05.118  0.303
2008 Potter H, Granic A, Boeras D, Crespo N, Padmanabhan J. P1-432: Alzheimer's mutant presenilin-1 and amyloid precursor protein genes cause chromosome missegregation and aneuploidy through the action of Abeta peptide Alzheimer's & Dementia. 4: T346-T346. DOI: 10.1016/J.Jalz.2008.05.1014  0.386
2007 Arendash GW, Jensen MT, Salem N, Hussein N, Cracchiolo J, Dickson A, Leighty R, Potter H. A diet high in omega-3 fatty acids does not improve or protect cognitive performance in Alzheimer's transgenic mice. Neuroscience. 149: 286-302. PMID 17904756 DOI: 10.1016/J.Neuroscience.2007.08.018  0.79
2007 Beekly DL, Ramos EM, Lee WW, Deitrich WD, Jacka ME, Wu J, Hubbard JL, Koepsell TD, Morris JC, Kukull WA, Reiman EM, Kowall N, Landreth G, Shelanski M, Welsh-Bohmer K, ... ... Potter H, et al. The National Alzheimer's Coordinating Center (NACC) database: The uniform data set Alzheimer Disease and Associated Disorders. 21: 249-258. PMID 17804958 DOI: 10.1097/Wad.0B013E318142774E  0.328
2007 Cracchiolo JR, Mori T, Nazian SJ, Tan J, Potter H, Arendash GW. Enhanced cognitive activity--over and above social or physical activity--is required to protect Alzheimer's mice against cognitive impairment, reduce Abeta deposition, and increase synaptic immunoreactivity. Neurobiology of Learning and Memory. 88: 277-94. PMID 17714960 DOI: 10.1016/J.Nlm.2007.07.007  0.404
2007 Costa DA, Cracchiolo JR, Bachstetter AD, Hughes TF, Bales KR, Paul SM, Mervis RF, Arendash GW, Potter H. Enrichment improves cognition in AD mice by amyloid-related and unrelated mechanisms. Neurobiology of Aging. 28: 831-44. PMID 16730391 DOI: 10.1016/J.Neurobiolaging.2006.04.009  0.695
2007 Arendash GW, Rezai-Zadeh K, Cao C, Mamcarz M, Dickson A, Schleif W, Runfeldt M, Lin X, Cracchiolo J, Shippy D, Raj A, Tan J, Potter H. O1-01-01: Caffeine: Evidence for protection against, and treatment for, Alzheimer's disease by direct suppression of disease pathogenesis Alzheimer's & Dementia. 3: S166-S166. DOI: 10.1016/J.Jalz.2007.04.355  0.695
2007 Potter H. S3-01-01: From diet and lifstyle factors to Alzheimer's mechanism and treatment Alzheimer's & Dementia. 3: S198-S198. DOI: 10.1016/J.Jalz.2007.04.008  0.331
2006 Padmanabhan J, Levy M, Dickson DW, Potter H. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons. Brain : a Journal of Neurology. 129: 3020-34. PMID 16987932 DOI: 10.1093/Brain/Awl255  0.439
2006 Boyd T, Woodcock JH, Adame V, Sillau SH, Borges TT, Bettcher BM, Daniels J, Heffernan KS, Potter H. P4-203: INTERIM BIOMARKER ANALYSES OF PHASE II STUDY DATA ON SAFETY AND EFFICACY OF GM-CSF/LEUKINE® IN MILD-TO-MODERATE AD Alzheimer's & Dementia. 14: P1517-P1518. DOI: 10.1016/J.Jalz.2018.07.024  0.734
2006 Potter H, Woodcock JH, Boyd T, Sillau SH, Borges TT, Bettcher BM, Daniels J, Heffernan KS. O1-12-01: PHASE II STUDY DATA ON SAFETY AND EFFICACY OF GM-CSF/LEUKINE® IN MILD-TO-MODERATE ALZHEIMER'S DISEASE Alzheimer's & Dementia. 14: P249-P249. DOI: 10.1016/J.Jalz.2018.06.2396  0.342
2006 Caneus J, Elos M, Potter H. P1-213: ELEVATED LEVELS OF MOSAIC ANEUPLOIDY IN HUNTINGTON'S DISEASE Alzheimer's & Dementia. 14: P360-P361. DOI: 10.1016/J.Jalz.2018.06.218  0.319
2006 Arndash GW, Cracchiolo JR, Costa DA, Mori T, Hughes TF, Bales KR, Paul SM, Potter H. P4-322: Complete environmental enrichment is required to protect AD transgenic mice against cognitive impairment, reduce a-beta deposition, and increase synaptophysin staining: Involvement of both amyloid-dependent and independent mechanisms Alzheimer's & Dementia. 2: S611-S611. DOI: 10.1016/J.Jalz.2006.05.2063  0.695
2006 Potter H, Boeras DI, Granic A, Padmanabhan J, Crespo NC, Crespo NC, Rojiani AM. P3-227: Chromosome aneuploidy, including human trisomy 21 caused by Alzheimer's mutant presenilin 1/ Î3 -secretase Alzheimer's & Dementia. 2: S442-S442. DOI: 10.1016/J.Jalz.2006.05.1496  0.73
2005 Potter H, Costa DA, Cracciola JR, Hughes T, Arendash GW. [O2-03-02]: Environmental enrichment prevents cognitive decline and induces memory-related gene expression in a mouse model of Alzheimer's disease Alzheimer's & Dementia. 1: S99-S99. DOI: 10.1016/J.Jalz.2005.06.343  0.652
2004 Costa DA, Nilsson LN, Bales KR, Paul SM, Potter H. Apolipoprotein is required for the formation of filamentous amyloid, but not for amorphous Abeta deposition, in an AbetaPP/PS double transgenic mouse model of Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 6: 509-14. PMID 15505373 DOI: 10.3233/Jad-2004-6508  0.696
2004 Nilsson LN, Arendash GW, Leighty RE, Costa DA, Low MA, Garcia MF, Cracciolo JR, Rojiani A, Wu X, Bales KR, Paul SM, Potter H. Cognitive impairment in PDAPP mice depends on ApoE and ACT-catalyzed amyloid formation. Neurobiology of Aging. 25: 1153-67. PMID 15312961 DOI: 10.1016/J.Neurobiolaging.2003.12.011  0.811
2004 Arendash GW, Garcia MF, Costa DA, Cracchiolo JR, Wefes IM, Potter H. Environmental enrichment improves cognition in aged Alzheimer's transgenic mice despite stable beta-amyloid deposition. Neuroreport. 15: 1751-4. PMID 15257141 DOI: 10.1097/01.Wnr.0000137183.68847.4E  0.689
2004 Leighty RE, Nilsson LN, Potter H, Costa DA, Low MA, Bales KR, Paul SM, Arendash GW. Use of multimetric statistical analysis to characterize and discriminate between the performance of four Alzheimer's transgenic mouse lines differing in Abeta deposition. Behavioural Brain Research. 153: 107-21. PMID 15219712 DOI: 10.1016/J.Bbr.2003.11.004  0.794
2004 Boeras DI, Granic A, Padmanabhan J, Potter H. P4-293 The presenilins, chromosome missegregation, and Alzheimer's disease Neurobiology of Aging. 25: S558. DOI: 10.1016/S0197-4580(04)81851-7  0.74
2004 Padmanabhan J, Potter H. P3-217 Aberrant mitosis specific protein phosphorylation in Alzheimer's disease Neurobiology of Aging. 25: S417. DOI: 10.1016/S0197-4580(04)81367-8  0.38
2004 Costa DA, Bales KR, Paul SM, Potter H. P2-302 Apolipoprotein E is required for filamentous, but not diffuse, amyloid deposition in an APP/PS mouse model of Alzheimer's disease Neurobiology of Aging. 25: S318-S319. DOI: 10.1016/S0197-4580(04)81047-9  0.675
2001 Potter H, Wefes IM, Nilsson LN. The inflammation-induced pathological chaperones ACT and apo-E are necessary catalysts of Alzheimer amyloid formation. Neurobiology of Aging. 22: 923-30. PMID 11755000 DOI: 10.1016/S0197-4580(01)00308-6  0.474
2001 Nilsson LN, Das S, Potter H. Effect of cytokines, dexamethasone and the A/T-signal peptide polymorphism on the expression of alpha(1)-antichymotrypsin in astrocytes: significance for Alzheimer's disease. Neurochemistry International. 39: 361-70. PMID 11578771 DOI: 10.1016/S0197-0186(01)00043-2  0.387
2001 Nilsson LN, Bales KR, DiCarlo G, Gordon MN, Morgan D, Paul SM, Potter H. Alpha-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 21: 1444-51. PMID 11222634  0.371
2001 Nilsson LNG, Bales KR, DiCarlo G, Gordon MN, Morgan D, Paul SM, Potter H. α-1-Antichymotrypsin Promotes β-Sheet Amyloid Plaque Deposition in a Transgenic Mouse Model of Alzheimer's Disease The Journal of Neuroscience. 21: 1444-1451. DOI: 10.1523/Jneurosci.21-05-01444.2001  0.45
2000 Potter H, Dressler D. The potential of BACE inhibitors for Alzheimer's therapy. Nature Biotechnology. 18: 125-6. PMID 10657070 DOI: 10.1038/72477  0.342
2000 Potter HP, Geller LN, Thomas AE, Conforto D, Chichkova RI. Cell cycle and chromosome segregation defects in alzheimer's disease Neurobiology of Aging. 21: 224. DOI: 10.1016/S0197-4580(00)83340-0  0.368
2000 Nilsson LN, DiCarlo G, Gordon MN, Morgan DG, Bales KR, Paul SM, Lilly E, Potter H. The role of alpha-1-antichymotrypsin (ACT) in abeta-amyloidosis of Alzheimer's disease, as studied in novel trigenic PDAPP, mapoe-knockout, GFAP-hACT transgenic mice strains Neurobiology of Aging. 21: 88. DOI: 10.1016/S0197-4580(00)82620-2  0.406
1999 Geller LN, Potter H. Chromosome missegregation and trisomy 21 mosaicism in Alzheimer's disease. Neurobiology of Disease. 6: 167-79. PMID 10408806 DOI: 10.1006/Nbdi.1999.0236  0.427
1999 Rogers JT, Leiter LM, McPhee J, Cahill CM, Zhan SS, Potter H, Nilsson LN. Translation of the alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5'-untranslated region sequences. The Journal of Biological Chemistry. 274: 6421-31. PMID 10037734 DOI: 10.1074/Jbc.274.10.6421  0.372
1999 Scinto LF, Rentz DM, Potter H, Daffner KR. Pupil assay and Alzheimer's disease: a critical analysis. Neurology. 52: 673-4. PMID 10025819 DOI: 10.1212/Wnl.52.3.673  0.362
1997 Li J, Xu M, Zhou H, Ma J, Potter H. Alzheimer presenilins in the nuclear membrane, interphase kinetochores, and centrosomes suggest a role in chromosome segregation. Cell. 90: 917-27. PMID 9298903 DOI: 10.1016/S0092-8674(00)80356-6  0.329
1997 Kayyali US, Zhang W, Yee AG, Seidman JG, Potter H. Cytoskeletal changes in the brains of mice lacking calcineurin A alpha. Journal of Neurochemistry. 68: 1668-78. PMID 9084440 DOI: 10.1046/J.1471-4159.1997.68041668.X  0.322
1996 Potter H. On keys and correlations in Alzheimer's disease Neurobiology of Aging. 17: 943-944. PMID 9363810 DOI: 10.1016/S0197-4580(96)00177-7  0.403
1996 Prihar G, Fuldner RA, Perez-Tur J, Lincoln S, Duff K, Crook R, Hardy J, Philips CA, Venter C, Talbot C, Clark RF, Goate A, Li J, Potter H, Karran E, et al. Structure and alternative splicing of the presenilin-2 gene. Neuroreport. 7: 1680-4. PMID 8904781 DOI: 10.1097/00001756-199607080-00031  0.33
1996 Ma J, Brewer HB, Potter H. Alzheimer Aβ neurotoxicity: Promotion by antichymotrypsin, ApoE4; inhibition by Aβ-related peptides Neurobiology of Aging. 17: 773-780. PMID 8892351 DOI: 10.1016/0197-4580(96)00112-1  0.408
1996 Potter H, Geller LN. Alzheimer's disease, Down's syndrome, and chromosome segregation [17] Lancet. 348: 66. PMID 8691961 DOI: 10.1016/S0140-6736(05)64399-1  0.355
1996 Potter H, Ma J, Li J, Geller L, Kayyali U, Zhon H, Xu M, Zhang S, Nilsson P, Dressler D, Zhang W, Seidman J. 760 Involvement of ACT, apoE, AD3/PS-1, AD4/PS-2, trisomy 21, and calcineurin in the development of amyloid deposits, neurofibrillary tangles and neurodegeneration in Alzheimer's disease Neurobiology of Aging. 17: S188-S189. DOI: 10.1016/S0197-4580(96)80762-7  0.466
1996 Li J, Ma J, Zhou H, Xu M, Nilsson P, Potter H. 54 Study of the AD3 and AD4 familial Alzheimer's disease genes Neurobiology of Aging. 17: S14. DOI: 10.1016/S0197-4580(96)80056-X  0.307
1995 Li J, Ma J, Potter H. Identification and expression analysis of a potential familial Alzheimer disease gene on chromosome 1 related to AD3 Proceedings of the National Academy of Sciences of the United States of America. 92: 12180-12184. PMID 8618867 DOI: 10.1073/Pnas.92.26.12180  0.407
1995 Das S, Potter H. Expression of the Alzheimer amyloid-promoting factor antichymotrypsin is induced in human astrocytes by IL-1 Neuron. 14: 447-456. PMID 7857652 DOI: 10.1016/0896-6273(95)90300-3  0.41
1994 Scinto LF, Daffner KR, Dressler D, Ransil BI, Rentz D, Weintraub S, Mesulam M, Potter H. A potential noninvasive neurobiological test for Alzheimer's disease. Science (New York, N.Y.). 266: 1051-4. PMID 7973660 DOI: 10.1126/Science.7973660  0.417
1994 Ma J, Yee A, Brewer HB, Das S, Potter H. Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments Nature. 372: 92-94. PMID 7969426 DOI: 10.1038/372092A0  0.425
1993 Nelson RB, Siman R, Iqbal MA, Potter H. Identification of a chymotrypsin-like mast cell protease in rat brain capable of generating the N-terminus of the Alzheimer amyloid β-protein Journal of Neurochemistry. 61: 567-577. PMID 8336143 DOI: 10.1111/J.1471-4159.1993.Tb02160.X  0.383
1992 Potter H, Nelson RB, Das S, Siman R, Kayyali US, Dressler D. The involvement of proteases, protease inhibitors, and an acute phase response in Alzheimer's disease Annals of the New York Academy of Sciences. 674: 161-173. PMID 1288361 DOI: 10.1111/J.1749-6632.1992.Tb27485.X  0.342
1992 Potter H. The involvement of astrocytes and an acute phase response in the amyloid deposition of Alzheimer's disease Progress in Brain Research. 94: 447-458. PMID 1287729 DOI: 10.1016/S0079-6123(08)61772-0  0.42
1991 Abraham CR, Driscoll J, Potter H, Van Nostrand WE, Tempst P. A calcium-activated protease from Alzheimer's disease brain cleaves at the N-terminus of the amyloid beta-protein. Biochemical and Biophysical Research Communications. 174: 790-6. PMID 1993072 DOI: 10.1016/0006-291X(91)91487-W  0.615
1991 Koo EH, Abraham CR, Potter H, Cork LC, Price DL. Developmental expression of alpha 1-antichymotrypsin in brain may be related to astrogliosis. Neurobiology of Aging. 12: 495-501. PMID 1837594 DOI: 10.1016/0197-4580(91)90079-Y  0.624
1990 Abraham CR, Shirahama T, Potter H. Alpha 1-antichymotrypsin is associated solely with amyloid deposits containing the beta-protein. Amyloid and cell localization of alpha 1-antichymotrypsin. Neurobiology of Aging. 11: 123-9. PMID 2190106 DOI: 10.1016/0197-4580(90)90045-2  0.638
1989 Abraham CR, Selkoe DJ, Potter H, Price DL, Cork LC. Alpha 1-antichymotrypsin is present together with the beta-protein in monkey brain amyloid deposits. Neuroscience. 32: 715-20. PMID 2689908 DOI: 10.1016/0306-4522(89)90292-3  0.701
1989 Abraham CR, Potter H. The protease inhibitor, alpha 1-antichymotrypsin, is a component of the brain amyloid deposits in normal aging and Alzheimer's disease. Annals of Medicine. 21: 77-81. PMID 2669847 DOI: 10.3109/07853898909149188  0.635
1989 Abraham CR, Potter H. Alpha 1-antichymotrypsin in brain aging and disease. Progress in Clinical and Biological Research. 317: 1037-48. PMID 2513582  0.587
1989 Pasternack J, Abraham C, Dyke BV, Potter H, Younkln S. ASTROCYTES IN ALZHEIMERʼS DISEASE GRAY MATTER EXPRESS α1 ANTICHYMOTRYPSIN mRNA Journal of Neuropathology and Experimental Neurology. 48: 328. DOI: 10.1097/00005072-198905000-00087  0.537
1989 Abraham CR, Potter H. Alzheimer's disease: Recent advances in understanding the brain amyloid deposits Bio/Technology. 7: 147-153. DOI: 10.1038/Nbt0289-147  0.644
1988 Abraham CR, Selkoe DJ, Potter H. Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell. 52: 487-501. PMID 3257719 DOI: 10.1016/0092-8674(88)90462-X  0.69
1988 ABRAHAM CR, SELKOE DJ, POTTER H. ??1-ANTICHYMOTRYPSIN IN BRAIN AGING AND DISEASE Alzheimer Disease & Associated Disorders. 2: 259. DOI: 10.1097/00002093-198802030-00108  0.638
Show low-probability matches.